Telemedicine is here to stay

Ipsos shares insights and tips to help pharma manufacturers modify their value proposition for long-term success.

The author(s)

  • Alex Colborn Account Manager, Health CS&F
  • Nimit Bansal Vice President, Health CS&F
Get in touch

COVID-19 has shifted the paradigm of healthcare delivery, turning medical visits once widely done in-person into a virtual experience for both physicians and patients. As telemedicine was slowly gaining traction in the U.S. healthcare system, the pandemic prompted a surge in its use as providers scrambled to keep their offices and healthcare facilities open as state lock­downs ensued. Ipsos studies earlier in 2020 and recent interviews with key healthcare stakeholders indicate that telemedicine is here to stay…but the critical question becomes: In what way? Will it find a niche role in certain areas in the post-COVID landscape where it is as effective as in-person visits, or will barriers prove too significant to overcome for telemedi­cine to persist long term?

Stakeholders across the healthcare space, including pharmaceutical manufacturers, must now account for this evolving treatment landscape. Companies must look to:

  • Develop a deeper understanding of the new patient journey
  • Support telemedicine usage among providers
  • Enable their products with appropriate support tools and programs to be successful in this new, telemedicine-enabled environment

Revisit our recorded webinar now, and download our detailed white paper which also features a Past Thinking + New Thinking map, together with our New Needs analysis and tips.

The author(s)

  • Alex Colborn Account Manager, Health CS&F
  • Nimit Bansal Vice President, Health CS&F

Society